^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Cholangiocarcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Transl Med
    Title:

    Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience

    Excerpt:
    Samples from 122 individual patients with ICC were analyzed….Eight patients with ERBB2 amplification received anti-HER2 therapy combined with basic chemotherapy...The median PFS time for trastuzumab-treated patients was 7.3 (1–27) months.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://dx.doi.org/10.1186%2Fs12967-020-02437-2
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification

    Published date:
    02/25/2021
    Excerpt:
    A 45-year-old woman...received surgery and pathological examination confirmed adenosquamous carcinoma. Fluorescence in Situ Hybridization (FISH) and Next-generation sequencing showed the tumor had Her-2 amplification….After progression, the patient received three cycles of albumin-bound paclitaxel combined with S-1 and trastuzumab and concurrent chemoradiotherapy (S-1) because of serious backache. Now, the disease is stable, and the PFS of 2nd line treatment (PFS2) has reached 7 months.
    Secondary therapy:
    albumin-bound paclitaxel + tegafur/uracil
    DOI:
    10.3389/fonc.2021.538328